Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bayer AG
Keeping Track: Entasis’ Antibiotic Xacduro, Two Opioid Misuse Therapies Clear US FDA; Pfizer’s Paxlovid Makes It Official
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain
The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a Pink Sheet analysis of FDA approval decisions since 2021.
Finance Watch: Mega-Round Mania As RNA Therapeutics, Gene Editing Attract VC Cash
Private Company Edition: Two companies raised multiple hundreds of millions of dollars each helping to keep the number of $100m-plus venture capital mega-rounds on the rise in May. Also, Ascend raised $132.5m to make gene and cell therapies, and Nido emerged with $109m for neurological diseases.
- In Vitro Diagnostics
- OTC, Consumer
- Radiopharmaceuticals, Contrast Agents
- Artificial Intelligence
- Other Names / Subsidiaries
- Actus Therapeutics, Inc.
- Asklepios BioPharmaceutical, Inc.
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
- Algeta ASA
- Bayer CropScience AG
- Bayer Consumer Care AG
- Berlex Laboratories
- BlueRock Therapeutics
- Conceptus Inc.
- Dihon Pharmaceutical Group Co., Ltd.
- Intendis GmbH
- Medrad Inc.
- Possis Medical
- Schering AG
- Monsanto Company
- Zeptosens AG
- KaNDy Therapeutics
- Vividion Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.